LXRX Stock Overview A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lexicon Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lexicon Pharmaceuticals Historical stock prices Current Share Price US$0.74 52 Week High US$3.73 52 Week Low US$0.62 Beta 1.05 1 Month Change -20.42% 3 Month Change -41.73% 1 Year Change -67.83% 3 Year Change -76.05% 5 Year Change -75.33% Change since IPO -99.44%
Recent News & Updates
New major risk - Shareholder dilution Jan 16 Lexicon Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Jan 08
Lexicon Pharmaceuticals, Inc. Announces CFO Changes Lexicon Appoints Scott Coiante as Chief Financial Officer Jan 02
New major risk - Share price stability Dec 26
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) Dec 21 See more updates
New major risk - Shareholder dilution Jan 16 Lexicon Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Jan 08
Lexicon Pharmaceuticals, Inc. Announces CFO Changes Lexicon Appoints Scott Coiante as Chief Financial Officer Jan 02
New major risk - Share price stability Dec 26
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) Dec 21
Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Nov 26
Price target decreased by 13% to US$4.68 Nov 22
Lexicon Pharmaceuticals, Inc. Announces Board Changes Nov 21
Consensus revenue estimates decrease by 24% Nov 20
New major risk - Financial position Nov 15
Price target increased by 16% to US$6.25 Nov 14
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 13
Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease Nov 06 Lexicon Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024
Price target decreased by 16% to US$5.40 Nov 03
Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease Nov 02
Consensus revenue estimates increase by 33% Oct 18
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes Oct 16
Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress Sep 27 Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer
Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial Sep 04
Consensus revenue estimates decrease by 41% Aug 09
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money Aug 08
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success Aug 03
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 02
Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission Jul 17
Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure Jul 15
High number of new directors Jul 10
Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer Jul 09 Lexicon Pharmaceuticals, Inc. Announces CEO Changes
Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association Jun 19
Price target increased by 13% to US$6.20 Jun 18
Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much May 28
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction May 15
New major risk - Shareholder dilution May 13
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 03
Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024 May 01 Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024
Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024 Mar 27
Consensus revenue estimates decrease by 44%, EPS upgraded Mar 18 Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A. Mar 14
New major risk - Share price stability Mar 12
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease Mar 12
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset Mar 12
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Mar 12 Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors. Mar 11
CEO & Director exercised options and sold US$161k worth of stock Mar 01
Consensus revenue estimates fall by 54% Feb 16
Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Jan 26
Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference Jan 09
Consensus revenue estimates decrease by 12% Dec 14
Price target decreased by 7.2% to US$5.15 Dec 13
Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain Nov 30
Independent Director recently bought US$202k worth of stock Nov 17
Consensus revenue estimates decrease by 31%, EPS upgraded Nov 15
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10
Price target increased by 30% to US$7.50 Nov 09
Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 04
Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023 Nov 01
Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting Oct 18
Independent Chairman of the Board recently bought US$1.1m worth of stock Oct 13
Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023 Oct 12
New minor risk - Share price stability Oct 11 Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients
Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes Sep 27
Consensus EPS estimates fall by 18% Aug 11
Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure Aug 09
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money Aug 08
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 04 Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors
Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023 Jul 25
CEO & Director recently bought US$92k worth of stock Jun 24
Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions Jun 21
Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure Jun 17
Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC Jun 07 Shareholder Returns LXRX US Biotechs US Market 7D -9.7% 3.5% 0.6% 1Y -67.8% 2.9% 22.4%
See full shareholder returns
Return vs Industry: LXRX underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: LXRX underperformed the US Market which returned 22.4% over the past year.
Price Volatility Is LXRX's price volatile compared to industry and market? LXRX volatility LXRX Average Weekly Movement 16.2% Biotechs Industry Average Movement 11.4% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: LXRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LXRX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Show more Lexicon Pharmaceuticals, Inc. Fundamentals Summary How do Lexicon Pharmaceuticals's earnings and revenue compare to its market cap? LXRX fundamental statistics Market cap US$270.22m Earnings (TTM ) -US$216.39m Revenue (TTM ) US$5.23m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LXRX income statement (TTM ) Revenue US$5.23m Cost of Revenue US$72.90m Gross Profit -US$67.67m Other Expenses US$148.73m Earnings -US$216.39m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.60 Gross Margin -1,294.05% Net Profit Margin -4,138.32% Debt/Equity Ratio 56.0%
How did LXRX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 22:49 End of Day Share Price 2025/02/06 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Lexicon Pharmaceuticals, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yigal Nochomovitz Citigroup Inc Kevin Kedra G. Research, LLC Joseph Pantginis H.C. Wainwright & Co.
Show 12 more analysts 
